Arcus Biosciences Total Liabilities 2017-2022 | RCUS

Arcus Biosciences total liabilities from 2017 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
Arcus Biosciences Annual Total Liabilities
(Millions of US $)
2021 $750
2020 $270
2019 $39
2018 $40
2017 $37
2016 $0
Arcus Biosciences Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $747
2021-12-31 $750
2021-09-30 $297
2021-06-30 $294
2021-03-31 $270
2020-12-31 $270
2020-09-30 $267
2020-06-30 $53
2020-03-31 $36
2019-12-31 $39
2019-09-30 $40
2019-06-30 $42
2019-03-31 $37
2018-12-31 $40
2018-09-30 $42
2018-06-30 $39
2018-03-31 $39
2017-12-31 $37
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.357B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00